Hypoalphalipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
imported>Meg Taylor (copyedit) |
||
| Line 8: | Line 8: | ||
==References== | ==References== | ||
{{reflist}} | |||
Revision as of 23:14, 19 February 2010
Hypoalphalipoproteinemias, also called familial high density lipoprotein deficiency disease and HDL lipoprotein deficiency disease, are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein A-I; lecithin cholesterol acyltransferase; and ATP-binding cassette transporters."[1]
Treatment
Using gemfibrozil to treat hypoalphalipoproteinemia may reduce major cardiovascular events[2] and stroke[3] and in men with known men with known coronary heart disease.
Using simvastatin plus niacin to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with coronary heart disease.[4]
References
- ↑ National Library of Medicine. Hypoalphalipoproteinemias. Retrieved on 2007-12-17.
- ↑ Rubins HB, Robins SJ, Collins D, et al (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259. [e]
- ↑ Bloomfield Rubins H, Davenport J, Babikian V, et al (2001). "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)". Circulation 103 (23): 2828–33. PMID 11401940. [e]
- ↑ Brown BG, Zhao XQ, Chait A, et al (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504. [e]